Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer

Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer

Shots:

  • The P-III HERO study involves assessing of Relugolix (360mg loading dose followed by 120mg, qd) vs leuprolide acetate (3mos. depot injection) in men in ratio 2:1 with androgen-sensitive advanced prostate cancer requiring at least 1yr. of continuous androgen deprivation therapy
  • The P-III HERO study resulted in meeting its 1EPs & all six key 2EPs i.e, 96.7% patients achieved sustained testosterone suppression to castrate levels & rapid and profound suppression of testosterone @4,15 and 15day, PSA suppression @15day, FSH suppression @24wks., non-inferior to leuprolide acetate on sustained testosterone suppression @48wks. (96.7% vs 88.8%) respectively
  • Relugolix is a GnRH receptor antagonist, acts by reducing testicular testosterone production with its anticipated NDA submission to the US FDA in Q2’20 and future regulatory submissions in Europe and Japan

Click here to­ read full press release/ article | Ref: Myovant | Image: Myovant